🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Italy / NCT05751577
Active, not recruiting Not applicable

TRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial

NCT05751577 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2023-05-01
Last updated
2026-04-08

Condition(s) studied

Aortic Stenosis, Severe

Investigational drug(s) / intervention(s)

TAVI WITHOUT ON-SITE SURGERYTAVI WITH ON-SITE SURGERY

TAVI WITHOUT ON-SITE SURGERY: After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery

TAVI WITH ON-SITE SURGERY: After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter

Study summary

The primary efficacy objective is to determine whether a TAVI procedure performed by experienced operators in centers without on-site cardiac surgery is noninferior to TAVI procedure performed by the same operators in centers with on-site cardiac surgery in terms of all-cause death, stroke and rehospitalization for cardiovascular cause. The primary safety objective is to demonstrate that mortality associated with periprocedural complications actionable by emergent cardiac surgery did not differ between study arms.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Severe aortic stenosis * Indication to TAVI confirmed by the Study Heart Team AND one of the following: * Inoperable due to prohibitive operative risk * High surgical risk as defined as STS score \>8% The presence of at least one clinical factor that, by unanimous judgment of the Study Heart Team, compromises the benefit/risk ratio in the case of emergent cardiac surgery: * Porcelain aorta or severely atherosclerotic aorta * Frailty/Reduced physical performance * Cognitive impairment, dementia, or Parkinson's disease * Severe liver disease/cirrhosis * Hostile chest * Internal mammalian artery or other critical conduit(s) crossing midline and/or adhering to the posterior table of the sternum * Severe pulmonary hypertension and/or severe right ventricular dysfunction * Severe Chronic Obstructive Pulmonary Disease (COPD) * Age ≥85 years Exclusion Criteria: * Unsuitable for transfemoral TAVI * Emergent TAVI * Noncardiovascular comorbidity reducing life expectancy to \<1 year * Any factor precluding 1-year follow-up * Refusal informed consent

Primary outcome measure(s)

Trial sites (14)

FacilityCityRegionStatus
Azienda Unità Sanitaria Locale Bologna Bologna
Ospedale San Donato di Arezzo Arezzo Italy
Ospedale Cardinal Massaia di Asti Asti Italy
Ospedale degli Infermi di Biella Biella Italy
Azienda Ospedaliero Universitaria di Ferrara Ferrara Italy
Ospedale "Morgagni - Pierantoni" di Forlì Forlì Italy
Ospedale Misericordia di Grosseto Grosseto Italy
Azienda ULSS 3 Serenissima, Ospedale di Mirano Mirano Italy
Ospedale Civile di Baggiovara Modena Italy
Ospedale Guglielmo da Saliceto di Piacenza Piacenza Italy
Ospedale Santa Maria delle Croci Ravenna Italy
Azienda Ospedaliera di Reggio Emilia Reggio Emilia Italy
Ospedale Infermi di Rimini Rimini Italy
Ospedale Civile di Venezia SS Giovanni e Paolo Venezia Italy

More Azienda Usl di Bologna trials in Italy

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05751577 on ClinicalTrials.gov ↗ ← All trials in Italy